ImmunoGen, Inc. (NASDAQ:IMGN) has been given a consensus recommendation of “Hold” by the eleven brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The average 1-year target […]
